Form 13-F position report

ULTRAGENYX PHARMACEUTICAL IN

Reported by Madison Avenue Partners LP

RARE CUSIP 90400D108 Manager CIK 0001801265

First reported at 1,705,351 shares this quarter.

New
% of reported 13F value 1.02% This manager · Q3 2026
Shares 1,705,351 Quarter-end amount reported
Reported value $25,631,426 Fair value at quarter end
Consecutive quarters held 1 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2026-09-30 25631426

Quarterly position history

How this manager's reported quarter-end position changed over time.

1 quarter
Quarterly reported position history for ULTRAGENYX PHARMACEUTICAL IN held by Madison Avenue Partners LP.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 New 1,705,351 +1,705,351 (0.0%) 1.02% $25,631,426 2026-11-16

Who else reported the position

348 managers reported ULTRAGENYX PHARMACEUTICAL IN for Q3 2026.

Managers reporting ULTRAGENYX PHARMACEUTICAL IN in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
BlackRock Inc Added 11,432,853 +778,577 < 0.01% $171,835,781 9 qtrs
RTW INVESTMENTS LP Added 8,529,394 +732,499 1.29% $128,196,792 20 qtrs
VANGUARD PORTFOLIO MANAGEMENT LLC Added 8,419,105 +1,628,970 < 0.01% $126,539,148 3 qtrs
STATE STREET CORPORATION Added 7,538,078 +1,379,312 < 0.01% $113,297,312 51 qtrs
VANGUARD CAPITAL MANAGEMENT LLC Added 4,299,168 +2,677 < 0.01% $64,616,495 3 qtrs
TWO SIGMA INVESTMENTS LP Reduced 3,130,527 -490,673 0.03% $47,051,821 26 qtrs
JACOBS LEVY EQUITY MANAGEMENT INC Reduced 2,900,418 -39,301 0.15% $43,593,283 6 qtrs
Nantahala Capital Management LLC New 2,339,293 +2,339,293 1.11% $35,159,574 1 qtr
GW&K Investment Management LLC Added 2,307,844 +826,666 0.29% $34,687,000 15 qtrs
GEODE CAPITAL MANAGEMENT LLC Reduced 2,174,052 -404,776 < 0.01% $32,683,698 51 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
November 16, 2026
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
1,705,351
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.